Daiken Biomedical Co., Ltd.
TTWSE:778015.65
TWD
-0.15
(-0.95%)
ISIN
TW0007780009
Return %
Stock
S&P 500
1Y
-13.77
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Tung Ching Lin
- Full Time Employees
- 58
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Taichung Taiwan
- IPO Date
- Oct 28, 2024
- Website
- daikenshop.com
- Similar Companies
- Business
- Daiken Biomedical Co., Ltd. is a Taiwan-based biotechnology and consumer health company engaged in the research, development, formulation, and commercialization of clinical-grade nutraceuticals, dietary supplements, and cosmeceutical skincare products. Founded in 2018 and headquartered in Taipei, Taiwan, the company operates as a key subsidiary of Sunfun Info Co., Ltd. and distributes its health solutions through an integrated data-driven direct-to-consumer (DTC) digital commerce infrastructure alongside omni-channel retail partnerships, including pharmacies and cosmeceutical chains. Daiken Biomedical offers an extensive portfolio of evidence-based health products organized across diverse wellness categories, comprising high-concentration omega-3 fish oil softgels manufactured using patented German KD-Pür supercritical rTG extraction technology for cardiovascular and cognitive health; vision care formulations featuring FloraGLO free-form lutein, zeaxanthin, and astaxanthin complexes; targeted gastrointestinal and microflora solutions, including high-potency daily probiotics, AP-66 immune support strains, and cranberry-infused urological probiotics; metabolic regulation products containing patented bitter melon peptides and botanical extracts for glycemic balance; vascular health supplements formulated with fermented natto kinase, Kaneka CoQ10, and monacolin K red yeast rice; joint and musculoskeletal support products incorporating UC-II undenatured type II collagen, hyaluronic acid, and vitamin D3; broad-spectrum nutritional essentials, including liposomal B-complex vitamins, bioavailable vitamin C, calcium, and mineral complexes; and advanced dermatological solutions, including medical-grade exosome anti-aging serums and revitalizing skincare treatments. In recent developments, Daiken Biomedical completed its transition from the Emerging Stock Board to a full public listing on the Taiwan Stock Exchange (TWSE: 7780) in September 2025, and subsequently executed a par value adjustment from NT$10 to NT$1 per share in early 2026 to enhance equity liquidity. The company has also expanded its geographic footprint across the Asia-Pacific region through the establishment of operating subsidiaries in Japan, Australia, and Hong Kong, while broadening its strategic partnerships with international raw material suppliers and diversifying its revenue base into high-margin aesthetic cosmeceuticals and exosome-based skincare technologies.